Acumen Pharmaceuticals
ABOS
47 hedge funds and large institutions have $120M invested in Acumen Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 19 closing their positions.
14% more capital invested
Capital invested by funds: $106M → $120M (+$14.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.71% less ownership
Funds ownership: 66.99% → 63.28% (-3.7%)
18% less funds holding
Funds holding: 57 → 47 (-10)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
50% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 20
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $82K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.21M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.2M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$2.07M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.88M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.28M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.25M |
| 3 |
Goldman Sachs
New York
|
-$1.15M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$1.13M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$878K |
ABOS Hedge Fund Activity: Q2 2022 in Review
47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q2 2022, worth a combined $120M — up 14% from $106M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ABOS and 11 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.21M. The largest seller was BlackRock, cutting an estimated $4.28M.
- 47 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q2 2022, down from 57 in Q1 2022.
- Funds reported $120M of Acumen Pharmaceuticals stock for Q2 2022, up 14% quarter-over-quarter.
- 11 funds opened new Acumen Pharmaceuticals positions in Q2 2022 and 19 closed out, a net change of -8 holders.
- The largest Acumen Pharmaceuticals buyer in Q2 2022 was Millennium Management, an estimated $2.21M added.
- The largest Acumen Pharmaceuticals seller in Q2 2022 was BlackRock, an estimated $4.28M sold.
Based on aggregated 13F filings for Q2 2022.